💸 The Tape

PharmaCielo Ltd. (TSXV: PCLO) (OTC Pink: PCLOF) reported fiscal Q1 revenue of $1.4 million, up from $0.3 million a year ago — a 330% increase driven by a broader geographic footprint and new flower sales to Europe.

Percentage growth from a base that small is the easiest headline in finance. What matters is what sits underneath it, and this quarter that's genuinely more encouraging than the last several. It's also not enough.

The operating picture

Gross profit reached $0.5 million, reversing a $0.1 million gross loss in the prior-year quarter. Gross profit before fair value adjustments came in at $707,000 against $33,000 — a twentyfold improvement, and the single most meaningful number in the release.

That's roughly a 51% gross margin before fair value adjustments, on a business that was selling product at essentially zero margin twelve months ago. Chairman and CEO Marc Lustig attributed it to stronger cannabis sales and a leaner operating platform, with focus on recurring export volumes, higher-value dried flower and extracts, and disciplined cost management.

Below that line, less progress. Adjusted EBITDA loss widened to $0.7 million from $0.4 million, which the company attributes to a one-time non-recurring expense. Net loss was $1.4 million versus $1.3 million — essentially flat, with loss per share unchanged at $0.007.

So: revenue up 330%, gross margin transformed, and the bottom line went nowhere. The cost base absorbed the gains.

Management states that with increasing volumes and a completely overhauled cost structure, the company expects to generate positive cash flow from operations going forward — and notes that major growth capex at its Production and Extraction Centre is complete.

The European flower angle is the real story

Strip away the small numbers and there's a legitimate strategic development here.

PharmaCielo's revenue growth came specifically from new flower sales to Europe. That places it in the same current everyone else is swimming in — Curaleaf went hostile on Aurora for EU-GMP tonnage, SNDL just cleared an EU-GMP audit at Atholville, Village Farms grew exports 74%, Decibel grew international 72%, Organigram bought Sanity Group for German distribution, and Rubicon landed CUMCS and IMC-G.A.P. certifications.

PharmaCielo's structural advantage is real and underappreciated: Colombian outdoor cultivation near the equator, with year-round growing seasons, low labor costs and natural light. On paper, it should be among the lowest-cost cannabis production on earth. The company also cites demand alignment across Latin America, Australia, South Africa and Europe.

The problem has never been the cost structure. It's been converting that advantage into recurring, contracted export volume — which requires working capital to hold inventory, EU-GMP-grade quality systems, and a balance sheet that lets you sell on terms rather than out of desperation.

Where the company actually stands

Here's the honest assessment, and it's uncomfortable.

Two months ago, PharmaCielo reported full-year results showing genuine repair work: the La Margarita property sold for roughly $10.0 million, generating a $2.2 million gain, with proceeds used to fully repay the Banco Agrario loan, make $3.6 million of debenture repayments and reduce other obligations. Full-year net loss narrowed to $3.6 million from $11.4 million. The Colombian subsidiaries turned cash-flow positive before Canadian corporate and financing costs.

That was real deleveraging. But it was accomplished by selling an asset, not by generating cash.

And the financing structure tells you where things stand. On August 24, following TSXV approval, PharmaCielo issued 9,721,443 common shares at an effective price of $0.08 to satisfy $777,717.33 of semi-annual interest on its 11% secured debentures. Share count now stands at 221,005,073.

Two things about that transaction deserve emphasis.

First, paying interest in stock at eight cents is dilution as a liquidity strategy. The company issued roughly 4.6% of its outstanding shares to cover a single semi-annual interest payment. Do that twice a year and you're diluting nearly 10% annually just to service debt — before any operational financing.

Second, the recipients. Interest shares went to L5 Capital Inc., Marc Lustig, William Petron and Ian Atacan — constituting a related-party transaction under MI 61-101. The company relied on exemptions from both formal valuation and minority approval requirements, on the basis that fair market value didn't exceed 25% of market capitalization.

Everything there is procedurally clean and disclosed. It also means insiders are converting company debt into equity at $0.08 without an independent valuation. That's not an accusation of bad faith — insiders funded the $2.8 million bridge loan when nobody else would, including $2.6 million from Lustig personally. But shareholders should understand that the people setting the terms are also receiving the shares.

The read

What's working: gross margin has genuinely inflected, European flower orders are real, growth capex is behind them, and the cost structure has been rebuilt. Colombia's production economics remain the best structural argument for owning this.

What isn't: $1.4 million in quarterly revenue against 11% secured debentures, insider bridge loans, and interest being paid in equity at eight cents. Adjusted EBITDA loss widened. Net loss is flat. The bottom line hasn't moved in a year.

What has to happen: the company needs recurring contracted export volume at multiples of current revenue, and it needs the working capital to fund it — which is precisely what it doesn't have. Management's positive-operating-cash-flow guidance is the whole thesis, and it's unproven.

Every major operator is now racing toward the exact market PharmaCielo was built to serve. It has the right asset in the right jurisdiction at the right moment — and the smallest balance sheet at the table.

📺 Trade To Black

Why DEA Came Out Guns Blazing for Reform | Trade to Black

• Adam Stettner puts the odds above 70% for Schedule III. The FundCanna CEO breaks down opponents' strongest counterargument — the shift from the old five-part medical-use test to the newer two-part standard — and explains why he still believes the recommendation lands on Schedule III despite that legal wrinkle, with timing closer to year-end than the midterms.

• What the transcript actually revealed. A theory on why DEA came out so strongly in favor during the hearing, plus the scale of medical participation now on the record: more than 30,000 practitioners treating over six million patients across 43 jurisdictions.

• The cost of uncertainty, from his own client base. Stettner shares real examples — including an operator running 18 attorneys and 11 accountants just to navigate the current environment — and explains why FundCanna has started separating medical and adult-use license types in its underwriting for the first time.

• Plus lending, banks, and Michigan. What happens to underwriting once 280E relief materializes, why institutions like First Citizens have been quietly positioning in hemp ahead of potential federal legalization, and the fight over Michigan's 24% wholesale tax.